Published January 1, 2021 | Version v1
Journal article Open

IRF5 inhibits prostate cancer metastasis and drug resistance by decreasing CXCR4/CXCL12 complex

  • 1. Adnan Menderes Univ, Dept Med Biochem, Sch Med, Aydin, Turkey
  • 2. Adnan Menderes Univ, Grad Sch Hlth Sci, Dept Med Biochem, Aydin, Turkey

Description

Purpose: Prostate cancer is the most common type of cancer in men, and drug resistance is typical in its treatment. Chemokines especially play a role in tumor growth and drug resistance mechanisms. IRF5 is a critical transcription factor in immune response, and its relationship with the chemokine family CXCR4 and CXCL12 was investigated in this study.

Files

bib-e600a9e6-46cc-4358-ba4b-dec1f4cb8ac0.txt

Files (189 Bytes)

Name Size Download all
md5:025e181ffb528efb50dee0dc927f38ee
189 Bytes Preview Download